Denosumab for the management of bone disease in patients with solid tumors.
about
Longitudinal patterns of bone-targeted agent use among patients with solid tumors and bone metastases in the United States.Aromatase inhibitors-induced bone loss in early breast cancer.Correlation of baseline biomarkers with clinical outcomes and response to fulvestrant with vandetanib or placebo in patients with bone predominant metastatic breast cancer: An OCOG ZAMBONEY sub-studySilibinin inhibits prostate cancer cells- and RANKL-induced osteoclastogenesis by targeting NFATc1, NF-κB, and AP-1 activation in RAW264.7 cells.Molecular target therapy for bone metastasis: starting a new era with denosumab, a RANKL inhibitor.The role of biochemical of bone turnover markers in osteoporosis and metabolic bone disease: a consensus paper of the Belgian Bone Club.
P2860
Denosumab for the management of bone disease in patients with solid tumors.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Denosumab for the management of bone disease in patients with solid tumors.
@en
Denosumab for the management of bone disease in patients with solid tumors.
@nl
type
label
Denosumab for the management of bone disease in patients with solid tumors.
@en
Denosumab for the management of bone disease in patients with solid tumors.
@nl
prefLabel
Denosumab for the management of bone disease in patients with solid tumors.
@en
Denosumab for the management of bone disease in patients with solid tumors.
@nl
P2860
P356
P1476
Denosumab for the management of bone disease in patients with solid tumors.
@en
P2093
Jean-Jacques Body
P2860
P304
P356
10.1586/ERA.11.204
P577
2011-12-22T00:00:00Z